英语释义

1. a hypotensive protease that liberates kinins from blood plasma proteins and is used therapeutically for vasodilation

片语

kallikrein inhibitors激肽释放酶抑制剂

recombinant kallikrein基因工程产品

human kallikrein人激肽释放酶

Kallikrein 6组织激肽释放酶

kallikrein from舒血管素

Kallikrein 14激肽释放酶

kallikrein gene激肽释放酶基因

pancreas kallikrein胰激肽释放酶

英汉例句

• the invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method.

  本发明涉及人尿激肽原酶用于治疗急性冠状动脉疾病的药物用途及按该方法制备的药物组合物。

• concluslons hort time use of kallikrein can improve the prognosis of patients with cerebral infarction, the probable mechanism is related to the decreased levels of serum mmp9.

  结论 短期应用尤瑞克林注射液可以改善脑梗死患者的预后，其机制可能与降低血清mmp9水平有关。

• objective the purpose of the present study was to explore the effect of kallikrein on pdgf induced proliferation of rat aortic vascular smooth muscle cells (vsmc).

  目的探讨了血管舒缓素对血小板趋化生长因子（pdgf）诱导培养的大鼠胸主动脉平滑肌细胞增殖的影响。

• aim: to investigate the expression of human kallikrein 15(klk15) in the primary epithelial ovarian carcinoma and the clinical significance.

  目的：研究上皮性卵巢癌组织中人类组织激肽释放酶15（klk15）蛋白的表达。

• conclusion human urinary kallikrein is effective and relatively safe in treatment of acute cerebral infarction in the vascular distribution of the internal carotid artery.

  结论人尿激肽原酶治疗急性颈内动脉系统脑梗死所致的神经功能缺损，其效果及安全性良好。

• the present invention relates to human tissue kallikrein, and is especially the microcapsulized cell of human tissue kallikrein and its microcapsulizing method and application.

  本发明涉及人组织激肽释放酶，具体地说是人组织激肽释放酶的微囊化细胞及其微囊化方法和应用；

• it was presumed that kbp may playa role in the regulation of metabolism of tissue kallikrein on the level of biosynthesis and excretion.

  推测kbp可能在合成和分泌的水平上，对组织激肽释放酶的代谢及活性起调节作用。

• conclusion it is safe and effective by using urinary kallikrein on acute cerebral infarction.

  结论尤瑞克林治疗急性脑梗死安全有效。

• to develop recombinant human pancreatic kallikrein and lay a foundation of hypertension.

  目的开发激肽释放酶基因工程产品，为开展基因治疗高血压奠定基础。

• we studied the mechanism of plasma and tissue kallikrein in activating plasminogen.

  作者研究了血浆和组织激肽释放酶激活纤溶酶原的机制。

• the kallikrein system, which produces the potent vasodilator bradykinin, is beginning to be studied.

  血管扩张物质缓激肽，有人正开始这种研究。

• the experiment showed that kallikrein in the mother solution in which elastase had been removed by sp resin could be prepared.

  实验结果表明：利用sp树脂吸附弹性酶 后 的母液仍可回收 胰激肽释放酶。

• on the cell of expressing human tissue kallikrein for gene modification, rigid envelope material with bi-directional flowability is coated.

  在基因修饰的表达人组织激肽释放酶的细胞上包覆着具有刚性和双向流通性的包膜材料；